NASDAQ:CYAD
Delisted
Celyad SA Stock News
$0.470
+0 (+0%)
At Close: Aug 17, 2023
What Makes Celyad SA (CYAD) a New Buy Stock
04:00pm, Tuesday, 31'st Mar 2020
Celyad SA (CYAD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Imagine Owning Celyad (EBR:CYAD) And Trying To Stomach The 84% Share Price Drop
08:42am, Thursday, 26'th Mar 2020
Celyad SA (EBR:CYAD) shareholders will doubtless be very grateful to see the share price up 43% in the last week. But...
Celyad (CYAD) Received its Third Buy in a Row
08:06pm, Wednesday, 25'th Mar 2020
After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from JonesTrading.
Celyad (CYAD) Received its Third Buy in a Row
08:05pm, Wednesday, 25'th Mar 2020
After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy,
William Blair Maintains Their Buy Rating on Celyad (CYAD)
05:16pm, Wednesday, 25'th Mar 2020
William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company's shares closed last Monday at $7.25. According to
William Blair Maintains Their Buy Rating on Celyad (CYAD)
05:16pm, Wednesday, 25'th Mar 2020
William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD – Research Report) today. The company’s shares closed
H.C. Wainwright Maintains Their Buy Rating on Celyad (CYAD)
05:07pm, Wednesday, 25'th Mar 2020
H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD) today and set a price target of $37.00. The company's shares closed last
H.C. Wainwright Maintains Their Buy Rating on Celyad (CYAD)
05:07pm, Wednesday, 25'th Mar 2020
H.C. Wainwright analyst
Edward White
maintained a
Buy
rating on Celyad (
CYAD
–
Research Report
) today and set a price target of
$37.00
. The company’s shares closed last Monday at $7.25.
Accordi
Celyad SA to Host Earnings Call
03:00pm, Wednesday, 25'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Celyad SA (NASDAQ:CYAD) will be discussing their earnings results in their 2019 Second Half Earnings call to be held on March 25, 2020 at 1:00 PM Eastern T
Celyad Reports Full Year 2019 Financial Results and Provides Business Update
11:36pm, Tuesday, 24'th Mar 2020
Regulatory News:
Celyad Reports Full Year 2019 Financial Results and Provides Business Update
11:23pm, Tuesday, 24'th Mar 2020
First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and.
Celyad to Announce Full Year 2019 Financial Results and Host Conference Call
08:01pm, Thursday, 12'th Mar 2020
MONT-SAINT-GUIBERT, Belgium, March 12, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
Celyad: Early Stage CAR-T Company With A Different Approach
02:55pm, Wednesday, 11'th Mar 2020
Celyad is developing both an autologous and allogeneic CAR-T platform to treat both hematological malignancies and solid tumors. Its lead allogeneic product can
Celyad Appoints Stephen Rubino as Chief Business Officer
06:00am, Monday, 02'nd Mar 2020
MONT-SAINT-GUIBERT, Belgium, March 02, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
Celyad Announces February and March 2020 Conference Schedule
06:00am, Monday, 17'th Feb 2020
MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
